HOME >> BIOLOGY >> NEWS
Discovering what genes do the high-throughput way

by the screen to characterize the effects of the RNAi treatment on the cells. They created a formal set of criteria to judge the cells consisting of seven classes of change that could have been induced. These included changes to cell number, shape, size and viability. Any changes were only considered significant if both scientists recorded them in replica experiments.

The researchers were also keen to find out if their method could be used to screen for genes that worked in, or inhibited specific molecular pathways. Screens in whole flies for genes that modify the effect of a particular genetic mutation have proved powerful, though time consuming. By adding two sets of double stranded RNA to each well, one that targeted the tumor suppressor gene pten and the other the gene to be tested, the researchers found that they were able to identify genes that modified the effects of inhibiting pten in cells. "These results demonstrate that modifier screens, as previously done in vivo, can be extended to RNAi screening methodology in cell culture", write the researchers.

Drug companies are becoming interested in this technique, as the rate-limiting step in cell-based drug discovery is finding out which protein is inhibited by a particular drug. Using Perrimon's method they can screen to see which gene, when inhibited, changes the cell in the same way as adding the drug.

"RNAi screens can complement classical Drosophila genetics to assign functions to both known and novel genes," write the researchers. "The same technology can be easily adapted to a wide variety of cell-based studies and a greater genomic scale."

Baum says, "The major difference between this and whole fly screens is that here we can be systematic. We can choose to look at any cell biological process and systematically test the set of genes that could be involved. In the future we will be able to screen the full genome in a few weeks, and look at any cell biological phenomenon.
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
30-Sep-2003


Page: 1 2 3

Related biology news :

1. Discovering new regulators of the immune system
2. Discovering the Tree of Life
3. Discovering Virology From Beijerinck To Hyperlinks
4. "Discovering Biological Diversity" Is AAAS Topic For USGS Manager
5. Belgian researchers explore revolutionary approach to angiogenesis
6. Tracing genes, biologists show lizard migration is traced to Florida
7. Certain genes boost fish oils protection against breast cancer
8. Fossil genes reveal how life sheds form and function
9. Missing genes may help explain why plague bacteria are so deadly
10. Do genes respond to global warming?
11. Genetic map of important tree genes outlined

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the ... offering. ... report provides separate comprehensive analytics for the US, Japan ... Annual estimates and forecasts are provided for the period 2015 through ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... BEACH, Fla. , Feb. 16, 2017 /PRNewswire/ ... company revolutionizing the development of liquid biopsy tests ... has entered into an exclusive license agreement with ... distribute MDNA,s proprietary liquid biopsy test for prostate ... South Korea . This is the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
Breaking Biology Technology:
Cached News: